Glympse Bio snags $22 mln Series A
Cambridge, Massachusetts-based Glympse Bio Inc, a provider of a platform that detects human diseases, has raised $22 million in Series A funding. LS Polaris Innovation Fund and ARCH Ventures led the round with participation from Charles River Ventures, Gilead Sciences, Yonghua Capital, Inevitable Ventures, GreatPoint Ventures, Heritage Provider Network and Rivas Capital.
9 October 2018•1 min read
